In ACHIEVE-4, 2,749 adults with type 2 diabetes, overweight or obesity, and established cardiovascular or kidney disease were randomised to oral orforglipron (up to 36 mg daily) or titrated insulin glargine. Over a median two years, MACE-4 (cardiovascular death, non-fatal MI, non-fatal stroke, unstable angina hospitalisation) occurred in 57 of 1,358 orforglipron participants (4.2%). The abstract cuts off before the comparator count and hazard ratio, so the formal non-inferiority result against the prespecified 1.8 margin cannot be confirmed here.
This is the first cardiovascular outcomes trial of a non-peptide GLP-1 receptor agonist, which matters because the proven benefits of semaglutide, liraglutide and dulaglutide cannot be assumed to transfer to a structurally different small molecule. The 1.8 margin is generous by modern standards, and non-inferiority against insulin glargine, a neutral comparator, would establish safety rather than benefit. Open-label design, only two years of follow-up and a modest event count limit what can be concluded about protection. Even so, a convenient oral agent without the fasting and food restrictions of oral semaglutide could widen access to GLP-1 therapy for people who avoid injections. Whether it reduces events, as injectables have in SUSTAIN-6, LEADER and REWIND, needs a dedicated superiority trial. Confirmatory rather than paradigm-shifting, but an essential regulatory step for the first oral small-molecule GLP-1 drug.